2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of … F Mach, C Baigent, AL Catapano, KC Koskinas, M Casula, L Badimon, ... European heart journal 41 (1), 111-188, 2020 | 9006 | 2020 |
2016 ESC/EAS guidelines for the management of dyslipidaemias AL Catapano, I Graham, G De Backer, O Wiklund, MJ Chapman, H Drexel, ... Polish Heart Journal (Kardiologia Polska) 74 (11), 1234-1318, 2016 | 8745* | 2016 |
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European … BA Ference, HN Ginsberg, I Graham, KK Ray, CJ Packard, E Bruckert, ... European heart journal 38 (32), 2459-2472, 2017 | 3497 | 2017 |
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of … BG Nordestgaard, MJ Chapman, SE Humphries, HN Ginsberg, L Masana, ... European heart journal 34 (45), 3478-3490, 2013 | 3107 | 2013 |
Lipoprotein (a) as a cardiovascular risk factor: current status BG Nordestgaard, MJ Chapman, K Ray, J Borén, F Andreotti, GF Watts, ... European heart journal 31 (23), 2844-2853, 2010 | 2205 | 2010 |
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management MJ Chapman, HN Ginsberg, P Amarenco, F Andreotti, J Borén, ... European heart journal 32 (11), 1345-1361, 2011 | 1627 | 2011 |
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, aetiology and management ES Stroes, PD Thompson, A Corsini, GD Vladutiu, FJ Raal, KK Ray, ... European heart journal 36 (17), 1012-1022, 2015 | 1556 | 2015 |
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European … J Boren, MJ Chapman, RM Krauss, CJ Packard, JF Bentzon, CJ Binder, ... European heart journal 41 (24), 2313-2330, 2020 | 1199 | 2020 |
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European … AL Catapano, Ž Reiner, G De Backer, I Graham, MR Taskinen, O Wiklund, ... Atherosclerosis 217, 1-44, 2011 | 1167 | 2011 |
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on … M Cuchel, E Bruckert, HN Ginsberg, FJ Raal, RD Santos, RA Hegele, ... European heart journal 35 (32), 2146-2157, 2014 | 1149 | 2014 |
Effect of two intensive statin regimens on progression of coronary disease SJ Nicholls, CM Ballantyne, PJ Barter, MJ Chapman, RM Erbel, P Libby, ... New England Journal of Medicine 365 (22), 2078-2087, 2011 | 1133 | 2011 |
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis PJ Barter, HB Brewer Jr, MJ Chapman, CH Hennekens, DJ Rader, ... Arteriosclerosis, thrombosis, and vascular biology 23 (2), 160-167, 2003 | 1126 | 2003 |
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis A Kontush, MJ Chapman Pharmacological reviews 58 (3), 342-374, 2006 | 989 | 2006 |
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment A Wiegman, SS Gidding, GF Watts, MJ Chapman, HN Ginsberg, M Cuchel, ... European heart journal 36 (36), 2425-2437, 2015 | 937 | 2015 |
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia JC Fruchart, F Sacks, MP Hermans, G Assmann, WV Brown, R Ceska, ... The American journal of cardiology 102 (10), 1K-34K, 2008 | 936* | 2008 |
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint … BG Nordestgaard, A Langsted, S Mora, G Kolovou, H Baum, E Bruckert, ... European heart journal 37 (25), 1944-1958, 2016 | 880 | 2016 |
Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets G Barba, F Harper, T Harada, M Kohara, S Goulinet, Y Matsuura, G Eder, ... Proceedings of the National Academy of Sciences 94 (4), 1200-1205, 1997 | 853 | 1997 |
Animal lipoproteins: chemistry, structure, and comparative aspects. MJ Chapman | 792 | 1981 |
Dysfunctional HDL and atherosclerotic cardiovascular disease RS Rosenson, HB Brewer Jr, BJ Ansell, P Barter, MJ Chapman, ... Nature reviews cardiology 13 (1), 48-60, 2016 | 764 | 2016 |
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes BA Ference, JG Robinson, RD Brook, AL Catapano, MJ Chapman, ... New England Journal of Medicine 375 (22), 2144-2153, 2016 | 743 | 2016 |